CareCloud (CCLD)
Market Price (3/4/2026): $2.46 | Market Cap: $104.2 MilSector: Health Care | Industry: Health Care Technology
CareCloud (CCLD)
Market Price (3/4/2026): $2.46Market Cap: $104.2 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 11%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 6.4%, FCF Yield is 17% | Weak multi-year price returns3Y Excs Rtn is -111% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -7.0% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15% | Key risksCCLD key risks include [1] the potential forced resignation of its public accounting firm and [2] geopolitical instability impacting its substantial operations in Pakistan and Sri Lanka. | |
| Megatrend and thematic driversMegatrends include Cloud Computing, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Telehealth Platforms, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 11%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 6.4%, FCF Yield is 17% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Megatrend and thematic driversMegatrends include Cloud Computing, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Telehealth Platforms, Show more. |
| Weak multi-year price returns3Y Excs Rtn is -111% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -7.0% |
| Key risksCCLD key risks include [1] the potential forced resignation of its public accounting firm and [2] geopolitical instability impacting its substantial operations in Pakistan and Sri Lanka. |
Qualitative Assessment
AI Analysis | Feedback
1. Anticipated decline in Q4 2025 earnings per share (EPS). Despite reporting Q3 2025 EPS of $0.10, exceeding analyst estimates of $0.08, the consensus forecast for CareCloud's Q4 2025 EPS is significantly lower at $0.04. This projected deceleration in earnings likely contributed to negative investor sentiment.
2. Significant shareholder dilution. The company experienced substantial dilution, with total shares outstanding growing by 160.8% over the past year.
Show more
Stock Movement Drivers
Fundamental Drivers
The -20.6% change in CCLD stock from 11/30/2025 to 3/3/2026 was primarily driven by a -20.6% change in the company's P/E Multiple.| (LTM values as of) | 11302025 | 3032026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.10 | 2.46 | -20.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 114 | 114 | 0.0% |
| Net Income Margin (%) | 9.8% | 9.8% | 0.0% |
| P/E Multiple | 11.7 | 9.3 | -20.6% |
| Shares Outstanding (Mil) | 42 | 42 | 0.0% |
| Cumulative Contribution | -20.6% |
Market Drivers
11/30/2025 to 3/3/2026| Return | Correlation | |
|---|---|---|
| CCLD | -20.6% | |
| Market (SPY) | -0.4% | 28.4% |
| Sector (XLV) | -0.6% | 9.8% |
Fundamental Drivers
The -35.9% change in CCLD stock from 8/31/2025 to 3/3/2026 was primarily driven by a -35.5% change in the company's P/E Multiple.| (LTM values as of) | 8312025 | 3032026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.84 | 2.46 | -35.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 112 | 114 | 2.3% |
| Net Income Margin (%) | 10.1% | 9.8% | -2.7% |
| P/E Multiple | 14.4 | 9.3 | -35.5% |
| Shares Outstanding (Mil) | 42 | 42 | -0.1% |
| Cumulative Contribution | -35.9% |
Market Drivers
8/31/2025 to 3/3/2026| Return | Correlation | |
|---|---|---|
| CCLD | -35.9% | |
| Market (SPY) | 5.8% | 25.6% |
| Sector (XLV) | 14.6% | 16.6% |
Fundamental Drivers
The -26.2% change in CCLD stock from 2/28/2025 to 3/3/2026 was primarily driven by a -61.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3032026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.33 | 2.46 | -26.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 111 | 114 | 3.0% |
| P/S Multiple | 0.5 | 0.9 | 87.4% |
| Shares Outstanding (Mil) | 16 | 42 | -61.8% |
| Cumulative Contribution | -26.2% |
Market Drivers
2/28/2025 to 3/3/2026| Return | Correlation | |
|---|---|---|
| CCLD | -26.2% | |
| Market (SPY) | 15.5% | 34.8% |
| Sector (XLV) | 6.6% | 15.7% |
Fundamental Drivers
The -34.7% change in CCLD stock from 2/28/2023 to 3/3/2026 was primarily driven by a -64.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3032026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.77 | 2.46 | -34.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 144 | 114 | -20.5% |
| Net Income Margin (%) | 5.9% | 9.8% | 66.7% |
| P/E Multiple | 6.8 | 9.3 | 37.7% |
| Shares Outstanding (Mil) | 15 | 42 | -64.2% |
| Cumulative Contribution | -34.7% |
Market Drivers
2/28/2023 to 3/3/2026| Return | Correlation | |
|---|---|---|
| CCLD | -34.7% | |
| Market (SPY) | 78.1% | 18.8% |
| Sector (XLV) | 29.0% | 9.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CCLD Return | -30% | -56% | -46% | 141% | -20% | -15% | -73% |
| Peers Return | -38% | -47% | -19% | -33% | -27% | -15% | -89% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 83% |
Monthly Win Rates [3] | |||||||
| CCLD Win Rate | 42% | 17% | 50% | 50% | 50% | 33% | |
| Peers Win Rate | 34% | 35% | 47% | 40% | 30% | 27% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 67% | |
Max Drawdowns [4] | |||||||
| CCLD Max Drawdown | -45% | -56% | -73% | -31% | -67% | -23% | |
| Peers Max Drawdown | -43% | -62% | -42% | -49% | -38% | -24% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PHR, TDOC, AMWL, HCAT, PRVA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/3/2026 (YTD)
How Low Can It Go
| Event | CCLD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -93.8% | -25.4% |
| % Gain to Breakeven | 1518.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -48.7% | -33.9% |
| % Gain to Breakeven | 95.1% | 51.3% |
| Time to Breakeven | 94 days | 148 days |
| 2018 Correction | ||
| % Loss | -54.4% | -19.8% |
| % Gain to Breakeven | 119.2% | 24.7% |
| Time to Breakeven | 13 days | 120 days |
Compare to PHR, TDOC, AMWL, HCAT, PRVA
In The Past
CareCloud's stock fell -93.8% during the 2022 Inflation Shock from a high on 2/9/2021. A -93.8% loss requires a 1518.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About CareCloud (CCLD)
AI Analysis | Feedback
Here are 1-2 brief analogies for CareCloud (CCLD):
- Salesforce for medical practices
- SAP for doctors' offices
AI Analysis | Feedback
- Electronic Health Records (EHR) System: A software platform for documenting, managing, and storing patient health information securely.
- Practice Management (PM) Software: Software that streamlines administrative tasks, scheduling, billing, and patient information management for healthcare practices.
- Revenue Cycle Management (RCM) Services: Comprehensive services that optimize the financial aspects of healthcare operations, from claims submission to payment collection.
- Telehealth Solutions: Platforms enabling virtual doctor-patient consultations and remote care delivery.
- Patient Experience Management: Tools and services designed to enhance patient engagement, communication, and satisfaction throughout their healthcare journey.
- Medical Scribing & Virtual Assistants: Services providing clinical documentation support to healthcare providers, often virtually, to reduce administrative burden.
AI Analysis | Feedback
CareCloud (CCLD) Major Customers
CareCloud (CCLD) primarily sells its healthcare information technology solutions to other companies, specifically healthcare provider organizations (B2B).
While CareCloud serves a wide array of customers, it does not publicly disclose the names of individual major customer companies. Its business model typically involves serving numerous healthcare practices and systems, with no single customer usually accounting for a material portion of its revenue that would necessitate individual disclosure in its financial filings.
CareCloud's major customer categories include:
- Small to mid-sized physician practices
- Multi-specialty groups and clinics
- Hospitals and health systems
- Ambulatory surgical centers (ASCs)
- Independent Physician Associations (IPAs)
- Other healthcare provider organizations seeking solutions for electronic health records (EHR), practice management, and revenue cycle management.
AI Analysis | Feedback
- Amazon Web Services (Parent company: Amazon.com, Inc., Symbol: AMZN)
AI Analysis | Feedback
Here is the management team for CareCloud (CCLD):A. Hadi Chaudhry Co-CEO
A. Hadi Chaudhry joined CareCloud, then known as MTBC, in October 2002 as an IT Manager. He has since held various key positions, including General Manager, Chief Information Officer, Vice President of Global Operations, and President, before becoming Co-CEO. With over two decades of experience in healthcare technology, operations, and organizational leadership, Mr. Chaudhry has been instrumental in CareCloud's transformation into a leading healthcare IT solutions provider. His background includes studies in mathematical sciences and statistics, a pursuit of a Chartered Accountant designation (similar to a CPA), and experience in the banking and IT sectors.
Stephen Snyder Co-CEO
Stephen Snyder joined CareCloud (formerly MTBC) in 2005 as General Counsel. He has held several influential roles within the company, including Chief Operating Officer, Chief Strategy Officer, and President, and previously served as CEO from 2018-2021. Mr. Snyder currently leads CareCloud's merger and acquisition (M&A) activities as an advisor, leveraging his expertise in healthcare IT, acquisitions, regulatory strategy, and healthcare law. He also founded Hill City Advisors, a firm that provides strategic guidance to healthcare entrepreneurs. Mr. Snyder is an attorney by background.
Norman Roth Interim Chief Financial Officer and Corporate Controller
Norman Roth serves as CareCloud's Interim Chief Financial Officer and Corporate Controller, bringing over 40 years of financial expertise to the company, which he joined in 2014. Prior to CareCloud, he worked as a forensic accountant since 2003 and served as Director of External Reporting, Treasury and Tax, and later Business Manager of WWOR-TV from 1991 to 2002. Mr. Roth began his career at Ernst & Young LLP in 1977, where he worked for 13 years, leaving as a senior manager. He is a Certified Public Accountant (CPA) and a certified fraud examiner.
Crystal Williams President
Crystal Williams was appointed President of CareCloud effective January 1, 2025. She has over two decades of leadership experience in Revenue Cycle Management (RCM), global operations, client success, credentialing, and coding. Before her promotion to President, she served as Chief Operating Officer at CareCloud. Prior to joining CareCloud in 2020, Ms. Williams held leadership roles at GE Healthcare IT, where she achieved Lean certification. Her background also includes systems and computer science, a graduate degree in public policy, and experience in management consulting and large-scale transformation initiatives.
Mahmud Haq Founder and Executive Chairman
Mahmud Haq founded CareCloud, originally known as Medical Transcription Billing Corporation (MTBC), in 1999. As Executive Chairman, he has been crucial in shaping the company's success. Before establishing CareCloud, Mr. Haq served as CEO and President of Compass International Services Corporation (NASDAQ: CMPS) from 1997 to 1999. He also spent over a decade at American Express (NYSE: AXP), where he held the position of Vice President of Global Risk Management.
AI Analysis | Feedback
The key risks to CareCloud's (CCLD) business include the potential resignation of its audit firm, geographical risks associated with its international operations, and intense competition within a rapidly evolving healthcare technology industry.
The most significant and immediate risk stems from the potential resignation of its current independent registered public accounting firm. This could occur if CareCloud's public float reaches or exceeds $75 million by June 30, 2025, which would classify it as an accelerated filer requiring an Internal Control over Financial Reporting (ICFR) attestation. CareCloud's current audit firm has stated it lacks the capacity for such an attestation, necessitating the engagement of a new accounting firm, which could lead to disruptions, additional costs, and complexities in the audit process.
CareCloud also faces significant geographical risks due to its substantial back-office operations located in Islamabad and Bagh, Pakistan, and Colombo, Sri Lanka. The company's business, financial condition, and results of operations may be materially influenced by the political, economic, and legal environments in these countries.
Furthermore, CareCloud operates in a highly competitive industry. Its competitors may possess greater resources or evolve more rapidly. The company must continually develop new technologies, including incorporating artificial intelligence, and adapt its existing technologies to keep pace with evolving industry standards and regulatory changes.
AI Analysis | Feedback
The entry of hyperscale technology companies (e.g., Amazon, Microsoft, Google) into the healthcare sector represents a clear emerging threat. These companies possess immense resources, advanced cloud infrastructure, and rapidly developing artificial intelligence capabilities, which they are leveraging to build integrated healthcare ecosystems. Their strategic acquisitions (e.g., Amazon's acquisition of One Medical, Microsoft's acquisition of Nuance) and product launches (e.g., Amazon Clinic, Microsoft Cloud for Healthcare) demonstrate a clear intent to offer comprehensive solutions that could encompass and potentially disrupt traditional healthcare IT offerings such as electronic health records (EHR), practice management (PM), and revenue cycle management (RCM) provided by companies like CareCloud. Their ability to deliver end-to-end platforms, potentially at a lower cost or with superior integration and user experience, poses a significant long-term competitive challenge.
AI Analysis | Feedback
CareCloud (CCLD) operates in the healthcare technology sector, providing a suite of cloud-based and AI-powered solutions for medical practices and health systems. Their main products and services include Revenue Cycle Management (RCM), Electronic Health Records (EHR), Practice Management (PM) software, and Telehealth services, as well as patient engagement and broader healthcare IT solutions. The addressable markets for these services in the U.S. are substantial:- U.S. Revenue Cycle Management (RCM) Market: The U.S. revenue cycle management market was estimated to be between USD 54.24 billion and USD 172.24 billion in 2024. It is projected to grow significantly, with estimates ranging from USD 100.52 billion by 2030 (CAGR 10.62%) to USD 308.2 billion by 2030 (CAGR 10.1%). Another projection indicates the market could reach USD 272.78 billion by 2030 at a CAGR of 11.55% from 2024.
- U.S. Electronic Health Records (EHR) Market: The U.S. electronic health records market size was estimated at approximately USD 12.87 billion in 2024 and is projected to grow at a CAGR of 2.55% from 2025 to 2030. Other estimates place the market size at USD 18.7 billion in 2024, growing to USD 19.4 billion in 2025. Another report valued the market at USD 34 billion in 2023, with a projected growth to USD 64.5 billion by 2032 at a CAGR of 7.4%.
- U.S. Practice Management (PM) Software Market: The U.S. practice management system market was estimated at approximately USD 5.89 billion in 2024, with another source reporting USD 9.61 billion in 2024. This market is projected to reach USD 13.70 billion by 2033 (CAGR 10.03%). The global practice management system market was USD 14.45 billion in 2024, with North America holding the largest revenue share.
- U.S. Telehealth Market: The U.S. telehealth market was valued between USD 42.54 billion and USD 42.61 billion in 2024. It is anticipated to grow significantly, with projections suggesting it could reach USD 150.13 billion by 2030 (CAGR 23.8%) and approximately USD 358.96 billion by 2034 (CAGR 23.84%).
- U.S. Healthcare IT Market (broader category): The broader U.S. healthcare IT software market was estimated at USD 166.83 billion in 2024 and is projected to grow at a CAGR of 15.46% from 2025 to 2030, reaching USD 388.99 billion by 2030. Another report estimates the U.S. healthcare IT market size at USD 176.6 billion in 2025. The total U.S. healthcare IT market was valued at USD 96.93 billion in 2020 and is projected to reach USD 344.07 billion by 2030.
AI Analysis | Feedback
CareCloud (CCLD) is anticipated to drive future revenue growth over the next 2-3 years through several key strategic initiatives:
- Strategic Acquisitions and Market Expansion: CareCloud's acquisition of Medsphere Systems Corporation's business assets and Map App are significant drivers. The Medsphere acquisition specifically expands CareCloud's presence into the inpatient hospital market, complementing its existing ambulatory solutions, revenue cycle, and technology-enabled services. This expansion into new market segments, particularly the hospital IT market, is expected to increase the company's scale and generate revenue. CareCloud has already raised its 2025 revenue guidance due to the Medsphere acquisition.
- AI-Driven Solutions and Innovation: The company is heavily investing in and advancing its AI-driven solutions, such as CareCloud CirrusAI and the Agentic AI front desk solution. These AI technologies are designed to streamline administrative tasks, improve clinical documentation, and manage patient interactions more efficiently, which can lead to increased provider capacity and patient volume. CareCloud has also launched an AI Center of Excellence to embed AI capabilities into its platforms. The Agentic AI front desk solution has shown success in managing a high percentage of incoming patient calls and appointment scheduling, showcasing the potential for these innovations to drive efficiency and, consequently, revenue.
- Cross-selling Opportunities: Following its strategic acquisitions, CareCloud anticipates significant cross-selling opportunities. By integrating acquired assets and expanding its service offerings, the company can leverage its broader portfolio to provide more comprehensive solutions to both new and existing clients, thereby increasing revenue per customer.
- Expanded Hospital Adoption: A direct consequence of the Medsphere acquisition and the expansion into the inpatient market is the expectation of expanded hospital adoption of CareCloud's offerings. As the company integrates Medsphere's solutions and gains a stronger foothold in the hospital sector, it anticipates increased client acquisition within this market segment.
- Organic Growth from Existing and New Clients: CareCloud's revenue guidance incorporates expectations for continued momentum from its core business, including revenue from existing clients and organic growth from new client additions. This indicates an ongoing focus on retaining and expanding its current customer base while also attracting new clients through its evolving product and service offerings. The company's consistent profitability and strong cash flow generation also provide a foundation to reinvest in future growth opportunities.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years)
Share Issuance
- In Q4 2024, CareCloud completed the conversion of 3.5 million Series A preferred shares into 26 million common shares, significantly reducing its annual dividend burden by $7.7 million.
- This conversion was a strategic move aimed at enhancing financial flexibility and demonstrating confidence in the company's profitability.
Outbound Investments
- CareCloud completed two strategic acquisitions in Q3 2025: Medsphere and MapApp.
- The Medsphere acquisition, completed around August 2025, had a total purchase price of $16.5 million, expanding CareCloud's reach into the hospital market.
- The acquisition of MapApp aims to enhance CareCloud's analytics and benchmarking capabilities.
Capital Expenditures
- For the 12 months ending November 6, 2025, CareCloud reported capital expenditures of approximately -$3.59 million.
- The company generated $13.2 million of free cash flow in 2024, an increase of 244% from $3.8 million in 2023.
- CareCloud has been focusing on reinvesting generated profits and cash flows for future growth, particularly in AI-driven solutions, with an AI Center of Excellence launched to scale generative AI initiatives.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| CareCloud Earnings Notes | 12/16/2025 | |
| Is CareCloud Stock Built to Withstand a Pullback? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CCLD.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 5.12 |
| Mkt Cap | 0.4 |
| Rev LTM | 390 |
| Op Inc LTM | -36 |
| FCF LTM | 26 |
| FCF 3Y Avg | -2 |
| CFO LTM | 43 |
| CFO 3Y Avg | 15 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.8% |
| Rev Chg 3Y Avg | 4.1% |
| Rev Chg Q | 4.4% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Mgn LTM | -4.5% |
| Op Mgn 3Y Avg | -14.7% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 8.5% |
| CFO/Rev 3Y Avg | 2.9% |
| FCF/Rev LTM | 5.5% |
| FCF/Rev 3Y Avg | -0.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.4 |
| P/S | 0.6 |
| P/EBIT | -1.2 |
| P/E | -1.0 |
| P/CFO | 3.6 |
| Total Yield | -12.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.2% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -7.2% |
| 3M Rtn | -25.5% |
| 6M Rtn | -33.2% |
| 12M Rtn | -43.5% |
| 3Y Rtn | -74.3% |
| 1M Excs Rtn | -5.4% |
| 3M Excs Rtn | -26.3% |
| 6M Excs Rtn | -40.5% |
| 12M Excs Rtn | -62.0% |
| 3Y Excs Rtn | -144.7% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Healthcare Information Technology (IT) | 104 | 125 | 127 | 93 | 51 |
| Medical Practice Management | 13 | 14 | 13 | 12 | 13 |
| Unallocated Corporate Expenses | 0 | ||||
| Total | 117 | 139 | 140 | 105 | 64 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Medical Practice Management | 1 | 1 | 0 | 0 | 0 |
| Unallocated Corporate Expenses | -9 | -9 | -8 | -6 | -5 |
| Healthcare Information Technology (IT) | -39 | 15 | 12 | -2 | 4 |
| Total | -47 | 7 | 4 | -8 | 0 |
Price Behavior
| Market Price | $2.46 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 07/23/2014 | |
| Distance from 52W High | -35.9% | |
| 50 Days | 200 Days | |
| DMA Price | $2.74 | $2.83 |
| DMA Trend | up | down |
| Distance from DMA | -10.2% | -12.9% |
| 3M | 1YR | |
| Volatility | 48.4% | 81.2% |
| Downside Capture | 170.48 | 157.87 |
| Upside Capture | 35.05 | 109.67 |
| Correlation (SPY) | 28.6% | 34.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.05 | 1.41 | 1.36 | 1.33 | 1.47 | 1.31 |
| Up Beta | 5.26 | 5.20 | 4.26 | 2.37 | 1.53 | 1.16 |
| Down Beta | -0.76 | 0.09 | 0.10 | 0.79 | 1.51 | 1.56 |
| Up Capture | 100% | 5% | 36% | 46% | 122% | 97% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 7 | 14 | 23 | 42 | 103 | 322 |
| Down Capture | 279% | 178% | 182% | 178% | 134% | 108% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 13 | 25 | 35 | 76 | 131 | 393 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCLD | |
|---|---|---|---|---|
| CCLD | -23.5% | 81.6% | 0.04 | - |
| Sector ETF (XLV) | 6.7% | 17.4% | 0.22 | 15.5% |
| Equity (SPY) | 15.6% | 19.3% | 0.63 | 34.6% |
| Gold (GLD) | 79.3% | 26.1% | 2.22 | -2.3% |
| Commodities (DBC) | 17.8% | 17.1% | 0.80 | 11.0% |
| Real Estate (VNQ) | 5.6% | 16.6% | 0.16 | 25.7% |
| Bitcoin (BTCUSD) | -18.7% | 45.2% | -0.32 | 19.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCLD | |
|---|---|---|---|---|
| CCLD | -26.4% | 90.3% | 0.04 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 12.3% |
| Equity (SPY) | 13.2% | 17.0% | 0.61 | 21.3% |
| Gold (GLD) | 22.8% | 17.3% | 1.08 | -0.8% |
| Commodities (DBC) | 10.8% | 19.0% | 0.46 | 2.6% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 17.8% |
| Bitcoin (BTCUSD) | 6.7% | 56.8% | 0.34 | 16.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCLD | |
|---|---|---|---|---|
| CCLD | 11.4% | 109.8% | 0.50 | - |
| Sector ETF (XLV) | 10.8% | 16.5% | 0.54 | 9.9% |
| Equity (SPY) | 15.3% | 17.9% | 0.74 | 15.0% |
| Gold (GLD) | 14.9% | 15.6% | 0.80 | 0.1% |
| Commodities (DBC) | 9.1% | 17.6% | 0.43 | 3.4% |
| Real Estate (VNQ) | 6.5% | 20.7% | 0.28 | 10.9% |
| Bitcoin (BTCUSD) | 66.5% | 66.8% | 1.06 | 9.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | 17.6% | 8.6% | 5.8% |
| 8/5/2025 | 0.0% | 7.6% | 53.4% |
| 3/13/2025 | 0.0% | 3.1% | -21.9% |
| 11/12/2024 | 21.5% | 6.9% | 51.3% |
| 8/13/2024 | 12.7% | 44.6% | 25.0% |
| 3/21/2024 | -6.7% | -0.8% | -4.2% |
| 11/2/2023 | 3.9% | 22.4% | 13.7% |
| 8/3/2023 | -11.4% | -26.9% | -48.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 8 | 9 |
| # Negative | 8 | 12 | 11 |
| Median Positive | 1.9% | 8.1% | 17.4% |
| Median Negative | -9.3% | -5.4% | -14.8% |
| Max Positive | 21.5% | 44.6% | 53.4% |
| Max Negative | -15.1% | -26.9% | -48.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 03/14/2022 | 10-K |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.